Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) was associated with a reduced risk for new ...

Continuing GLP-1 RA use through surgery increases risk for surgical complications including aspiration and conversion to intubation ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

However, overall, the absolute risk for thyroid cancer is low. (HealthDay News) — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist ...

Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual ...

Patients who continued Ozempic through total joint arthroplasty had the highest risk for complications. HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 ...